Key result
Rb+ in hERG assays reduces drug affinity up to ~10-fold vs K+ by modulating channel inactivation.
Why the study?
The nonradioactive Rb+ efflux assay is limited by low sensitivity for potent hERG blockers, and the underlying reasons for this limitation were unclear.
The use of Rb+ in high-throughput hERG screening assays reduces the apparent affinity of hERG-blocking drugs by altering channel inactivation properties, explaining the assay's low sensitivity.
Urges caution interpreting Rb+ efflux results for potent hERG blockers; leaves open refinement of high-throughput assays with K+.
The nonradioactive Rb+ efflux assay has become a reliable and efficient high-throughput hERG screening method, but it is limited by its low sensitivity for potent hERG blockers. Using the patch clamp technique, the authors found that the low sensitivity is due in part to the use of Rb+ as the permeating cation in the assay. The affinities of the drugs measured by patch clamp technique in the presence of Rb+ were 3- to 10-fold lower than when measured by the same method in the presence of K+ ions. The apparent affinity of the drugs decreased even further when monitored by the Rb+ efflux assay. It was also observed that Rb+ had minimal effects on the activation properties of channels while there was a significant change in the half-inactivation potential. This voltage shift reduces hERG channel inactivation at efflux assay potentials, and will reduce the affinity of hERG-blocking drugs that bind to inactivated states of the channel. In combination with the effects of elevated extracellular ion concentrations, it is likely that Rb+ modulation of hERG channel inactivation is largely responsible for the reduced drug potencies observed in the Rb+ efflux assay.
No takes yet. Share an insight, caveat, or question.
Rezazadeh et al. (2004) studied this question. Rb+ as permeating cation vs. K+ ions was evaluated on Drug affinity for hERG channels. Using Rb+ as the permeating cation in hERG screening assays reduces the measured affinity of channel-blocking drugs by 3- to 10-fold compared to K+ ions, likely due to modulation of channel inactivation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: